Follow
Vanessa (Gray) Hasle
Vanessa (Gray) Hasle
Principal Scientist at Bristol Myers Squibb
Verified email at bms.com
Title
Cited by
Cited by
Year
Multiplex assessment of protein variant abundance by massively parallel sequencing
KA Matreyek, LM Starita, JJ Stephany, B Martin, MA Chiasson, VE Gray, ...
Nature genetics 50 (6), 874-882, 2018
4312018
Quantitative Missense Variant Effect Prediction Using Large-Scale Mutagenesis Data
DMF Vanessa E. Gray, Ronald J. Hause, Jens Luebeck, Jay Shendure
Cell Systems, 2017
212*2017
Analysis of large-scale mutagenesis data to assess the impact of single amino acid substitutions
VE Gray, RJ Hause, DM Fowler
Genetics 207 (1), 53-61, 2017
1462017
Efficacy and safety of azacitidine (AZA) in combination with the anti-PD-L1 durvalumab (durva) for the front-line treatment of older patients (pts) with acute myeloid leukemia …
AM Zeidan, J Cavenagh, MT Voso, D Taussig, M Tormo, I Boss, ...
Blood 134, 829, 2019
832019
Evolutionary diagnosis method for variants in personal exomes
S Kumar, M Sanderford, VE Gray, J Ye, L Liu
Nature Methods 9 (9), 855 - 856, 2012
702012
A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML
AM Zeidan, I Boss, CL Beach, WB Copeland, E Thompson, BA Fox, ...
Blood Advances 6 (7), 2219-2229, 2022
672022
Performance of computational tools in evaluating the functional impact of laboratory-induced amino acid mutations
VE Gray, KR Kukurba, S Kumar
Bioinformatics 28 (16), 2093-2096, 2012
662012
A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes
AM Zeidan, I Boss, CL Beach, WB Copeland, E Thompson, BA Fox, ...
Blood Advances 6 (7), 2207-2218, 2022
422022
Elucidating the Molecular Determinants of Aβ Aggregation with Deep Mutational Scanning
DMF Vanessa E. Gray, Katherine Sitko, Floriane Z. Ngako Kameni, Miriam ...
G3: GENES, GENOMES, GENETICS 9 (11), 3683-3689, 2019
402019
Rampant Purifying Selection Conserves Positions with Posttranslational Modifications in Human Proteins
VE Gray, S Kumar
Molecular Biology and Evolution 28 (5), 1565, 2011
322011
A molecular evolutionary reference for the human variome
L Liu, K Tamura, M Sanderford, VE Gray, S Kumar
Molecular biology and evolution 33 (1), 245-254, 2015
282015
Multiplexed immunofluorescence (IF) analysis and gene expression profiling of biopsies from patients with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL …
DJ Reiss, T Do, D Kuo, VE Gray, NE Olson, CW Lee, MH Young, ...
Blood 134, 202, 2019
212019
Prognostic implications of mono-hit and multi-hit TP53 alterations in patients with acute myeloid leukemia and higher risk myelodysplastic syndromes treated with …
AM Zeidan, JP Bewersdorf, V Hasle, RM Shallis, E Thompson, ...
Leukemia 37 (1), 240-243, 2023
122023
Signatures of natural selection on mutations of residues with multiple posttranslational modifications
VE Gray, L Liu, R Nirankari, PV Hornbeck, S Kumar
Molecular biology and evolution 31 (7), 1641-1645, 2014
122014
Quantitative missense variant effect prediction using large-scale mutagenesis data. Cell Syst 6 (116–124): e3
VE Gray, RJ Hause, J Luebeck, J Shendure, DM Fowler
102018
Using large-scale mutagenesis to guide single amino acid scanning experiments
VE Gray, RJ Hause, DM Fowler
BioRxiv, 140707, 2017
52017
The Evolutionary History of Amino Acid Variations Mediating Increased Resistance of S. aureus Identifies Reversion Mutations in Metabolic Regulators
SK Mia D. Champion, Vanessa Gray, Carl Eberhard
PLOS ONE 8 (2), 2013
52013
Molecular, epigenetic, and immune landscape of TP53-mutated (TP53-M) acute myeloid leukemia (AML) and higher risk myelodysplastic syndromes (HR-MDS)
JP Bewersdorf, V Hasle, RM Shallis, EG Thompson, D Lopes de Menezes, ...
Blood 140 (Supplement 1), 6247-6249, 2022
42022
Immune and epigenetic landscape of TP53-mutated acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (HR-MDS)
AM Zeidan, JPP Bewersdorf, V Hasle, EG Thompson, DL de Menezes, ...
Blood 138, 3371, 2021
32021
Integrated genetic, epigenetic, and immune landscape of TP53 mutant AML and higher risk MDS treated with azacitidine
AM Zeidan, JP Bewersdorf, V Hasle, RM Shallis, E Thompson, ...
Therapeutic Advances in Hematology 15, 20406207241257904, 2024
22024
The system can't perform the operation now. Try again later.
Articles 1–20